|Day Low/High||294.03 / 302.60|
|52 Wk Low/High||193.11 / 314.00|
Let's check the charts of three drug names, Merck, Eli Lilly and Bristol-Myers Squibb.
LLY is looking shaky, despite fundamental improvements from its weight-loss drug tirzepatide.
Upside - +74% (enters strategic agreement with Immune Therapeutics for rights to low dose naltrexone) - +18% (earnings, guidance) - +16% (earnings, guidance) - +14% (earnings) - +11% (earnings, guidance) - +10% (earnings, guidance) - +9.1% (highligh...
Wednesday's session was dominated by traders, algorithmic traders for sure, but traders nonetheless. The PMs mostly sat on their hands.
A couple bearish divergences indicate that the pace of the advance in the giant drugmaker's shares is slowing.
Recently poor sector performance is creating opportunity for long-term investors.
Just a week ago Jerome Powell referred to the labor market as 'strong.' Now, economists, traders, investors, and the public are just not quite sure what to expect Friday.
Unless you are a great stock picker and timer, a strategy of taking profits into available strength the next two months is key.
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
Markets are pricing in some fiscal policy, but it's not what a lot of pundits think.
Next Week (Selected Macro) Monday AM: PM: Tuesday AM: , , , , , PM: , , , Wednesday AM: , , , PM: , , Thursday AM: PM: , , Friday AM: , PM: none Next Week (Selected Macro) Monday: Dallas Fed Manufacturing Index Tuesday: Case-Sh...
Pockets of speculative trading are narrower, but the appetite for action has not disappeared.
What if areas of expected growth in labor market demand moving forward do not materialize?
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?
Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.
Let's check out the LLY charts amid FDA approval of the company's Alzheimer's drug.
This market is moving in so many areas that you have to marvel at how it's even possible -- even if the Russell Rebalancing could change all that on Friday.
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
Let's look at the companies that can go up, and the ones that can't.
Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'
With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.
I have become a huge devotee of this simple option strategy. Here are two recent examples from this week.
Let's look at this impossible move on the market -- and why health care could be coming off life support.
Let's review the charts and indicators.